IMMUNOVIA

About us

Immunovia, Inc. is the exclusive provider of the IMMray® PanCan-d test, a blood test for the early detection of pancreatic adenocarcinoma (PDAC).

 
IMMray-1.jpg
 

The IMMray PanCan-d test relies on the IMMray microarray technology, where single chain fragment antibodies are produced and then printed onto a slide in a measured amount as a microarray of different antibody biomarkers. 14 microarrays are printed on each slide.

IMMray-2.jpg

When a patient’s serum sample is received at Immunovia, Inc., the patient’s serum is biotinylated and then applied to the microarray; the microarray is scannedusing a fluorescence scanner to measure antibody responses to patient serum; and then antibody response levels are entered into an algorithm to determine a result of “High-Risk Signature Present”, “Negative for High-Risk Signature” or Borderline result.

 TALK TO US 

Chat Live with us on August 6th, 2021

JOIN THE LIVE EVENT

IMMUNOVIA, Inc.

immunoviainc.com

26 Forest Street, Suite 110 Marlborough, MA 01752

MEAGAN LUIPOLD

Meagan.luipold@immunovia.com

508-613-8212

Return to the MAGIC 2021 Conference Streaming

 
 

Search tags: Pancreatic Cancer, Laboratory Test, Biomarkers, Blood Test